Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

This publication has 29 references indexed in Scilit:

• Bezafibrate for the Secondary Prevention of Myocardial Infarction in Patients With Metabolic Syndrome
  Archives of internal medicine (1960), 2005
• Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)
  American Journal of Kidney Diseases, 2005
• Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis
  Atherosclerosis, 2004
• Systematic review of lipid lowering for primary prevention of coronary heart disease in diabetes
  BMJ, 2003
• Dynamic balanced randomization for clinical trials
  Statistics in Medicine, 1993
• WHO clofibrate/cholesterol trial: clarifications
  The Lancet, 1992
• LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes.
  Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992
• Coronary Heart Disease Incidence in NIDDM Patients In The Helsinki Heart Study
  Diabetes Care, 1992
• Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
  New England Journal of Medicine, 1987
• Serum lipids and lipoproteins in middle-aged non-insulin-dependent diabetics
  Atherosclerosis, 1985